Dublin, Nov. 10, 2015 (GLOBE NEWSWIRE) -- Research and Markets ( http://www.researchandmarkets.com/research/tz...checkpoint ) has announced the addition of the "Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025" report to their offering. Cancer is known to be one of the leading causes of death worldwide. The field of oncology is vast and comprises several indications, including some rare / orphan forms. Although oncology continues to be one of the most active areas in terms of drug development, there is still a significant unmet need. The focus of drug developers is gradually moving towards immunotherapeutics, which make use of the body's own immune system or its components to fight cancer. It is a relatively new concept, with the only success being targeted antibody based therapeutics (including monoclonal and conjugated antibodies). Interest has surged in other classes of immunotherapeutics; these include Immune Checkpoint Inhibitors, therapeutic cancer vaccines and other whole cell based therapies. Immune checkpoints are molecules that regulate (stimulate or inactivate) the immune cells. Yervoy (an anti CTLA-4 drug), the foremost drug to be launched in this domain, is currently being mirrored by various other drugs such as Opdivo, Keytruda (both anti PD-1 drugs) and many under clinical development. The market, with an opportunistic development pipeline, caters to the participation of various market players (big and small) over a common platform.With an ongoing rush to emerge as leaders in the evolving market, various stakeholders have collaborated to establish their foothold in a relatively short time period. In addition to the marketed drugs (Yervoy, Opdivo and Keytruda), we expect a number of drugs currently in advanced stages of development (Tremelimumab, Elotuzumab, RG7446 and Avelumab)to achieve blockbuster status in the near future. The anticipated success of Immune Checkpoint Inhibitors shall prove to be a harbinger for emerging players and a strong impetus to the development pace of the other pharmaceutical giants. The Immune Checkpoint Inhibitors Market (2nd edition), 2015-2025 report provides a comprehensive analysis of the current market landscape and the future outlook of the growing pipeline of Immune Checkpoint Inhibitors. The immuno-oncology market encompasses a myriad of immune checkpoint targeting drugs which can be potentially exploited for a broad range of cancer indications. Specifically, CTLA-4 inhibitors were the pioneers in this segment. Yervoy, the flagship molecule from BMS, was the only immunotherapeutic commercially available until other classes recently stepped in. The recent approval of anti PD-1 drugs and emergence of anti PD-L1 drugs has provided a significant boost to the market. In addition, there are several novel checkpoint inhibitors (e.g. IDO, LAG-3, CD70, OX40, CD40, GITR, TIM-3, CD137/4-1BB, KIR, TDO, VISTA, CS1, NKG2A, GARP, ICOS) which have recently gained ground and are expected to retain attention in the future. One of the key objectives of the study is to review the prospects laid by the robust, opportunistic and broad pipelines of the pharmaceutical firms. With three marketed drugs (Yervoy, Keytruda and Opdivo), the market is treading its way towards fulfilling the huge untapped promise.
Amongst other elements, the report elaborates upon the following key areas: - The current state of the market with respect to key players, developmental stage of pipeline products (both clinical / pre-clinical) and indications targeted - Recent partnerships which have taken place over the last five years including product co-development, licensing and clinical trial collaborations - Combination therapies where Immune Checkpoint Inhibitors are being evaluated in combination with other anti-cancer agents/therapies - Various investments and grants received by the companies focused in this area - Competitive landscape and inherent threats to growth in the short and long term - Development and sales potential based on target consumer segments, likely adoption rate and expected pricing The base year for the report is 2015. The report provides the market forecast for the period 2015-2025, respectively. The research, analysis and insights presented in this report include potential sales of several Immune Checkpoint Inhibitors; this analysis is backed by a deep understanding of key drivers behind the growth.
Example Highlights: - The industry is characterized by the presence of three marketed drugs and 34 drugs in clinical development for oncological indications. The marketed and clinical pipeline includes two CTLA-4, nine PD-1 / PD-L1 and 26 novel Immune Checkpoint Inhibitors.The dynamic pipeline also includes several molecules in preclinical/ discovery stage; in our research, we identified about 70 such molecules. - BMS, with tenImmune Checkpoint Inhibitors (marketed / under development), is the leading player. Other pharmaceutical giants include AstraZeneca, Merck & Co, Pfizer, Merck KGaA, Roche, GSK, Novartis and Amgen. - Many start-ups, small companies and university spin-offs have also emerged in the past two years. Examples (in alphabetical order) include Agenus, Alligator Bioscience, Ambrx, AnaptysBio, arGEN-X, Bioceros, BioNovion, Cellerant Therapeutics, Checkpoint Therapeutics, Compugen, CureTech, Enumeral, Five Prime Therapeutics, Genmab, GITR, ImmuNext, IOmet Pharma, iTeos Therapeutics, Jounce Therapeutics, KAHR Medical, Multimeric Biotherapeutics, Nativis, Orega Biotech, Pelican Therapeutics, Pieris Pharmaceuticals, Prima BioMed, Redx Pharma, Sorrento Therapeutics,Tesaro, TG Therapeutics, Theravectys and ToleroTech. - Amongst the novel Immune Checkpoint Inhibitors, IDO inhibitors have gained maximum attention; this is followed by molecules targeting LAG-3, CD-70, OX-40 and CD-40. Although Elotuzumab is the only drug in late stage development, novel checkpoints have paved the way for smaller biotechnology firms to enter the immuno-oncology market. - Collaborations have helped the market reach its current growth trajectory.Specifically, clinical trial collaborations to evaluate Immune Checkpoint Inhibitors as combination therapies are very common; the period Jan 2014-May 2015 saw over 40 such collaborations for a number of molecules. - We expect Immune Checkpoint Inhibitors to be a multi-billion dollar market over the coming decade; during the period 2015 - 2025, our forecast suggests that the market will witness an annualized growth rate of 27.7%. Companies Mentioned - 4-Antibody - 5 AM Ventures - Abbott - AbbVie - Acerta Pharma BV - Adimab - Advanced Technology Ventures - Advaxis - Agenus - AgonOX - Alden Cancer Therapy II - Alexandria Real Estate - Allen & Company - Alligator Bioscience - Alloy Ventures - Alta Partners - Altor Bioscience - Ambrx - American Cancer Society - American Society of Hematology - Amgen - Amplimmune - AnaptysBio - Anderson Cancer Center - Aravis Ventures - Arcus Ventures - arGEN-X - ARMO BioSciences - AstraZeneca - Aurigene - Avalon Ventures - Aventis - Azienda Ospedaliera Universitaria Senese - Banque Internationale - Bayer - BeiGene - Belgian Walloon Government - Belgium and BPI - Beth Israel Deaconess Medical Center - BioWa - Bioceros - Biogen Idec New Ventures - BioGeneration Ventures - BioInvent International AB - Bio-Matrix Scientific Group - BioNovion - Boxer Capital of Tavistock Life Science - Brabant Development Agency - Brabant Life Sciences Seed Fund - Bristol Myers Squibb - Caisse de dpt et placement du Qubec - California Pacific Medical Center Research Institute - Camelot Ventures - Cancer Research Institute - Casdin Capital - Celldex Therapeutics - Cellerant Therapeutics - Centocor Ortho Biotech - Checkpoint Therapeutics - Chiron - CIDC - CITIC Capital Holdings - Clal Biotechnology Industries - CMEA Capital - Cogene BioTech Ventures - Cold Genesys - Compugen - Cormorant Asset Management - CoStim Pharmaceuticals - Crédit Agricole Private Equity - Curadev - CureTech - Curis - CX Venture Group - Dana-Farber Cancer Institute - de Duve Institute - Deerfield Management and Leerink Swann - Dendreon - Diamond Capital Company Ltd - Domain Associates - Dynavax Technologies - Eddingpharm - Eisai - Eli Lilly and Company - EMD Serono - Emerging Technology Partners - Eminent Venture Capital Corp - Endocyte - Enumeral Biomedical Holdings - Erasmus MC Biomedical Fund - ESCO Congress - Ethe Erasmus Biomedical Fund - European Regional Development Fund - European Society for Medical Oncology - Evogene - Facet Biotech - Fidelity Management & Research - Five Prime Therapeutics - Flexus Bioscience - Forbion Capital Partners - Foresite Capital - Frazier Healthcare Partners - Fred Hutchinson Cancer Research Center - Genentech - Genmab - Genzyme - George Rathmann - Gilead - GITR Inc. - GlaxoSmithKline - Grupo Español Multidisciplinar de Melanoma - H. Lee Moffitt Cancer Center and Research Institute - Hadasit Bio Holdings - Harris & Harris Group - Harvard University - Healthcap Venture Capital - HealthCare Ventures - Heat Biologics - Hillhouse Capital Group - Hoffmann-La Roche - Home Capital AS - Hoosier Cancer Research Network - Hunt Ventures - Hunza Ventures SCA - Imclone - ImmuNext - Immunocore - ImmuTep - Incyte Corporation - Innate Pharma - Innovis Investments - Inserm Transfert Initiative - Institut Bergonié - Institute for the Promotion of Innovation by Science and Technology in Flanders - InterWest Partners - IOmet Pharma - iTeos Therapeutics - Janssen Biotech - Johns Hopkins University - Jonsson Comprehensive Cancer Center - Jounce Therapeutics - Juno Therapeutics - Kadmon Corporation - KAHR Medical - KBC Securities - Keddem Bioscience - Kleiner Perkins Caufield & Byers - Kyowa Hakko Kirin - Laureate Pharma - Lee's Pharmaceutical - Ludwig Cancer Research - Life Sciences Partners - Lonza Biologics - Ludwig Institute for Cancer Research - M.D. Anderson Cancer Center - MacroGenics - Malmsten Invest - Mark Tompkins Montrose Capital - Masonic Cancer Center - Massachusetts Institute of Technology - Maverick Capital - Medarex - Medicare - MedImmune - Medivation - Melanoma Institute, Australia - Memorial Sloan Kettering Cancer Center - Merck & Co - Merck KGaA - Merck Serono Ventures - Mithra Ventures - Mitsubishi UFJ - MorphoSys - Morphotek - MPM Capital - Multimeric Biotherapeutics - NantWorks - National Cancer Institute - National Institutes of Health - Nativis - NCIC Clinical Trials Group - Neviah Genomics - New Enterprise Associates - New York University School of Medicine - NewLink Genetics - Nextech Venture - Nordic Venture Capital Investor Sunstone Capital - Northwest Regional Development Agency - Novartis - Novel Bioventures - Novo Nordisk - Numenor Ventures - Octalfa - Ohio State University Comprehensive Cancer Center - Omega Funds - Oncothyreon - Ono Pharmaceuticals - Onyx Pharmaceuticals - OPKO Health - Oracle Partners - OrbiMed - Orega Biotech - Organon - Orphan Medical - Pappas Ventures - PDL Biopharma - Pelican Therapeutics - Pfizer - Pharmacyclics - Pharmstandard - Pieris Pharmaceuticals - Pierre Fabre - Plexxikon - Prima BioMed - Prometheus Laboratories - Providence Health & Services - Ragon Institute of Massachusetts General Hospital - Recipharm - Red Abbey Venture Partners - Redmile Group - Redx Pharma - Regis Technologies - Rhône-Alpes Création - RiverVest Venture Partners - Rock Springs Capital - Roswell Park Cancer Institute - Samsung Biologics - Sanofi - Schering Plough Brinny Co. - Scottish Venture Fund - Seattle Genetics - Sequoia Capital - Servier - Seventure Partners - SHAM - Sharp & Dohme Corp. - Sidney Kimmel Comprehensive Cancer Center - Singapore BioInnovations - Society of Melanoma Research International Congress - Sorrento Therapeutics - Southwest Oncology Group - Spring Bioscience - Syndax Pharmaceuticals - Synta Pharmaceuticals - Takara Bio Inc. - Tavistock Life Sciences - Tesaro - TetraLogic Pharmaceuticals - Texas Pacific Group Ventures - TG Therapeutics - The Leukemia and Lymphoma Society - The University of Texas MD Anderson Cancer Center - The Wellcome Trust - Theravectys - Third Rock Ventures - Thomas Jefferson University - Thuja Capital Healthcare Funds - ToleroTech - Tolerx - TPG Ventures - Transparency Commission - Université Catholique de Louvain - United Therapeutics - University Hospital Southampton NHS Foundation Trust - University of California, Davis - University of Iowa Pharmaceutical Services - University of Minnesota - University of Pittsburgh - University of Texas - University of Utah - Ventana Medical Systems - Ventures West - Versant Ventures - Vlaams Instituut voor Biotechnologie - Vinnova - Viralytics - VIVES Louvain Technology Fund - Vivo Ventures - VLST Corporation - Walloon - Washington University School of Medicine - Wellcome Trust Sanger Institute - Wellington Management - WS Investments - Wyeth For more information visit http://www.researchandmarkets.com/research/tz...checkpoint
CONTACT: Research and Markets Laura Wood, Senior Manager press@researchandmarkets.com For E.S.T Office Hours Call 1-917-300-0470 For U.S./CAN Toll Free Call 1-800-526-8630 For GMT Office Hours Call +353-1-416-8900 U.S. Fax: 646-607-1907 Fax (outside U.S.): +353-1-481-1716 Sector: Medical Devices, Immune Disorders, Oncology
